Pharmaceutical & Drug Policy
The myth of the free market for pharmaceuticals
On November 19, the Engelberg Center for Health Care Reform at Brookings hosted an event examining the outlook and opportunities for biomedical innovation in a challenging fiscal environment. Leaders in the field offered their thoughts on future directions of and policy priorities for the innovation enterprise. Following a brief keynote, a panel of senior thought leaders provided further discussion on actionable next steps to improve biomedical innovation.
Download the executive summary » (PDF)
Download the panelist biographies » (PDF)
New Policy Directions for Biomedical Innovation
Agenda
-
November 19
-
Priorities for Biomedical Innovation in a Challenging Fiscal Environment
1:45 pm
EPEd Penhoet Director - Alta Partners -
Finding the Path Forward for Biomedical Innovation
2:25 pm
CAChristopher Austin Director, National Center for Advancing Translational Sciences - National Institutes of HealthDBDeborah Brooks Co-Founder and Executive Vice Chairman - The Michael J. Fox FoundationRCRobert Conley Regulatory Leader and Distinguished Lilly Scholar - Eli Lilly and CompanyJMJohn Mendelsohn Professor, Department of Experimental Therapeutics, Division of Cancer Medicine and Director, Khalifa Institute for Personalized Cancer Therapy - The University of Texas MD Anderson Cancer CenterESEarl Steinberg Executive Vice President of Innovation & Dissemination - Geisinger Health Solutions
-
